Medicine
Xifaxan 200 mg tablet
Xifaxan 200 mg tablet is a prescription medicine containing Rifaximin for oral use, marketed by Salix Pharmaceuticals, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store XIFAXAN Tablets at 20° to 25°C (68° to 77°F), excursions permitted to…
Key facts
- Active ingredient (INN)
- Rifaximin
- Brand
- Xifaxan
- Strength
- 200 mg
- Dosage form
- Tablet
- Route
- Oral
- Packs
- 30 tablets, 9 tablets
- Marketing authorisation holder
- Salix Pharmaceuticals
- Manufacturers
- Salix PharmaceuticalsA-S Medication Solutions
- Origin register
- US FDA, United States
- Storage
- Store XIFAXAN Tablets at 20° to 25°C (68° to 77°F), excursions permitted to 15° to 30°C (59° to 86°F).
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- A07AA11 Rifaximin
- HS code (indicative)
- 3004.20Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 25 July 2004
- Identifiers
- RxCUI 429662, 539789, 856664 +1DailyMed set ID c5e8e2fd-7087-4b78-9181-cc259c0be2f1, f73acb74-e930-4414-81e9-d2a01db36e30NDC 65649-301, 50090-2445Application NDA021361
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 30 tablet in 1 bottle | 65649-301-03 | Salix Pharmaceuticals | 25 July 2004 |
| 9 tablet in 1 bottle | 50090-2445-0 | A-S Medication Solutions | 8 August 2016 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 25 May 2004 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Rifaximin
Clinical summary
Rifaximin is a rifamycin antibacterial indicated for treatment of travelers’ diarrhea (TD) caused by noninvasive strains of Escherichia coli in adult and pediatric patients 12 years of age and older, among other approved uses. MedsAcross supplies Rifaximin for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about RifaximinFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- XIFAXAN prescribing information (Salix Pharmaceuticals) · U.S. National Library of Medicine, DailyMed
Need Xifaxan 200 mg tablet for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.